EVTRATYMPANIC DEXAMETHASONE IN DIABETIC AND HYPERTENSIVE PATIENTS WITH SUDDEN SENSORINEURAL HEARING LOSS
|Full paper||Not Available|
Systemic steroid therapy has been considered a mainstay for treat ment qfidiopathic sudden sensorineural hearing loss (ISSNHL), specially among those who suspect a viral etiology. Unfortunately, some patients are poor candidates for systemic steroids. The aim of the present study is to evaluate the efftcacy of intratympanic dexamethasone injection for diabetic and hypertensive patients with SSNHL in whom systemic ster oid therapy is hazardous. This study was undertaken prospecttvely on 26 diabetic and hypertensive patients with unilateral moderately severe and severe SSNHL in whom there was a history of a recent upper respira tory tract infection. The patients were 14 men (53.8%) and 12 women (46.2%) with an age range 43-68 years. Under local anaesthesia, 0.5.ml of dexamethasone (24 mg/ml) was injected in the tympanic cavity, injec tion was performed on three separate occasions over 10 days. Hearing was assessed by pure-tone and speech audiometry immediately before, twice weekly during therapy and within 3 weeks after therapy was dis continued. Pure-tone average (500, 1000 and 2000Hz) improved in 15 patients (57.7%). 7patients (27%) recovered to normal hearing threshold levels , 5 patients (19.2%) improved to a degree of mild hearing loss and 3 patients (11.5%) improved to a degree of moderate hearing loss. A hear ing recovery rate of 57.7% in ISSNHL could be considered a good and encouraging response rate in a group of patients who can not tolerate systemic steroid therapy and may be considered beyond therapeutic reach.